GlaxoSmithKline Biologicals SA v. Moderna, Inc.
1:24-cv-01135
Overview
Parties
Defendant
ModernaTX, Inc. Operating Company
Represented By
16 Attorneys ListedFarnan LLP
919 North Market Street, 12th Floor
Farnan LLP
919 North Market Street, 12th Floor
Farnan LLP
919 North Market Street, 12th Floor
Plaintiff
GlaxoSmithKline Biologicals SA NPE (University / Research)
Represented By
17 Attorneys ListedRichards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Richards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Special Master
Monte T. Squire NPE (Individual / Inventor)
Represented By
0 Attorneys ListedCounter Claimant
GlaxoSmithKline LLC NPE (University / Research)
Represented By
17 Attorneys ListedRichards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Richards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Counter Defendant
Moderna US, Inc. Operating Company
Represented By
16 Attorneys ListedFarnan LLP
919 North Market Street, 12th Floor
Farnan LLP
919 North Market Street, 12th Floor
Farnan LLP
919 North Market Street, 12th Floor
Moderna, Inc. Operating Company
Represented By
16 Attorneys ListedFarnan LLP
919 North Market Street, 12th Floor
Farnan LLP
919 North Market Street, 12th Floor
Farnan LLP
919 North Market Street, 12th Floor
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 19 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 11,291,682 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,596,645 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,730,754 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,690,861 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,707,482 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,690,862 B1 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,865,080 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,690,864 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,857,562 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,690,865 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,696,923 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,690,863 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,759,475 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,717,529 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 12,186,333 B2 | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There are 7 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US11291682
Delivery of RNA to trigger multiple immune pathways
|
Filed: 2019-07-16
Issued: 2022-04-05
|
Active (12.7 yrs remaining)
Expires: 2039-07-16
|
|
|
US11324770
Delivery of RNA to trigger multiple immune pathways
|
Filed: 2020-01-13
Issued: 2022-05-10
|
Active (5.4 yrs remaining)
Expires: 2032-04-02
|
|
|
US11596645
Delivery of RNA to trigger multiple immune pathways
|
Filed: 2021-10-27
Issued: 2023-03-07
|
Active (14.9 yrs remaining)
Expires: 2041-10-27
|
|
|
US11666534
Methods of administering lipid formulations with viral immunogens
|
Filed: 2021-12-22
Issued: 2023-06-06
|
Active (15.1 yrs remaining)
Expires: 2041-12-22
|
|
|
US11690862
Delivery of RNA to trigger multiple immune pathways
|
Filed: 2022-12-13
Issued: 2023-07-04
|
Active (4.6 yrs remaining)
Expires: 2031-07-06
|
Patent Enforceability & Injunction Risk Assessment
Active Threat — Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.
Standard Statutory Term — No obviousness-type double patenting truncation noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. 4th Year Maintenance Fee Paid (8th Year Window Upcoming).
Procedural Motions & Interlocutory Orders
Total Motions
97
Dispositive
21
Granted
1
Denied
4
Pending / Review
72
Motions by Category
Key Dispositive Motions & Rulings